Skip to main content
Journal cover image

Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders.

Publication ,  Journal Article
Faber, BM; Mayer, J; Cox, B; Jones, D; Toner, JP; Oehninger, S; Muasher, SJ
Published in: Fertil Steril
May 1998

OBJECTIVE: To evaluate the pregnancy results of an ovarian hyperstimulation protocol for IVF-ET that combines GnRH agonist down-regulation, cessation of GnRH agonist therapy with the onset of menstruation, and high-dose gonadotropin administration in low responders. DESIGN: Prospective analysis. SETTING: Academic IVF program. PATIENT(S): One hundred eighty-two low responders undergoing 224 IVF-ET cycles. INTERVENTION(S): Down-regulation was obtained with the administration of leuprolide acetate beginning in the midluteal phase and ending with the onset of menses. Daily administration of 6 ampules of FSH alone or in combination with hMG was initiated on cycle day 3. MAIN OUTCOME MEASURE(S): Stimulation characteristics and pregnancy rates (PRs) were compared between fresh cycles in which pure FSH alone was used and 35 cycles in which a combination of FSH and hMG was administered. RESULT(S): The clinical PR per transfer, the ongoing PR per transfer, and the implantation rate were 32%, 24%, and 9%, respectively. No differences were noted between cycles in which pure FSH alone was used in comparison with cycles in which a combination of FSH and hMG was administered. CONCLUSION(S): Short-term ovarian suppression begun in the luteal phase and discontinued with the onset of menses followed by high-dose stimulation with gonadotropins yields favorable pregnancy results in low responders.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Fertil Steril

DOI

ISSN

0015-0282

Publication Date

May 1998

Volume

69

Issue

5

Start / End Page

826 / 830

Location

United States

Related Subject Headings

  • Prospective Studies
  • Pregnancy
  • Obstetrics & Reproductive Medicine
  • Menotropins
  • Luteinizing Hormone
  • Leuprolide
  • Humans
  • Follicle Stimulating Hormone
  • Fertilization in Vitro
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Faber, B. M., Mayer, J., Cox, B., Jones, D., Toner, J. P., Oehninger, S., & Muasher, S. J. (1998). Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders. Fertil Steril, 69(5), 826–830. https://doi.org/10.1016/s0015-0282(98)00040-5
Faber, B. M., J. Mayer, B. Cox, D. Jones, J. P. Toner, S. Oehninger, and S. J. Muasher. “Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders.Fertil Steril 69, no. 5 (May 1998): 826–30. https://doi.org/10.1016/s0015-0282(98)00040-5.
Faber, B. M., et al. “Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders.Fertil Steril, vol. 69, no. 5, May 1998, pp. 826–30. Pubmed, doi:10.1016/s0015-0282(98)00040-5.
Faber BM, Mayer J, Cox B, Jones D, Toner JP, Oehninger S, Muasher SJ. Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders. Fertil Steril. 1998 May;69(5):826–830.
Journal cover image

Published In

Fertil Steril

DOI

ISSN

0015-0282

Publication Date

May 1998

Volume

69

Issue

5

Start / End Page

826 / 830

Location

United States

Related Subject Headings

  • Prospective Studies
  • Pregnancy
  • Obstetrics & Reproductive Medicine
  • Menotropins
  • Luteinizing Hormone
  • Leuprolide
  • Humans
  • Follicle Stimulating Hormone
  • Fertilization in Vitro
  • Female